HomeCompareAIFER vs ABBV

AIFER vs ABBV: Dividend Comparison 2026

AIFER yields 911.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AIFER wins by $8448980.28M in total portfolio value
10 years
AIFER
AIFER
● Live price
911.58%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8448980.39M
Annual income
$6,949,337,622,226.25
Full AIFER calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AIFER vs ABBV

📍 AIFER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIFERABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIFER + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIFER pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIFER
Annual income on $10K today (after 15% tax)
$77,484.05/yr
After 10yr DRIP, annual income (after tax)
$5,906,936,978,892.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, AIFER beats the other by $5,906,936,957,836.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIFER + ABBV for your $10,000?

AIFER: 50%ABBV: 50%
100% ABBV50/50100% AIFER
Portfolio after 10yr
$4224490.24M
Annual income
$3,474,668,823,499.00/yr
Blended yield
82.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AIFER
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIFER buys
0
ABBV buys
0
No recent congressional trades found for AIFER or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIFERABBV
Forward yield911.58%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8448980.39M$102.3K
Annual income after 10y$6,949,337,622,226.25$24,771.77
Total dividends collected$8332836.42M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AIFER vs ABBV ($10,000, DRIP)

YearAIFER PortfolioAIFER Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$101,858$91,157.70$11,550$430.00+$90.3KAIFER
2$976,755$867,767.68$13,472$627.96+$963.3KAIFER
3$8,822,120$7,776,991.94$15,906$926.08+$8.81MAIFER
4$75,086,688$65,647,019.38$19,071$1,382.55+$75.07MAIFER
5$602,523,930$522,181,174.11$23,302$2,095.81+$602.50MAIFER
6$4,560,755,620$3,916,055,014.86$29,150$3,237.93+$4560.73MAIFER
7$32,583,053,567$27,703,045,053.04$37,536$5,121.41+$32583.02MAIFER
8$219,832,766,118$184,968,898,801.44$50,079$8,338.38+$219832.72MAIFER
9$1,401,535,292,766$1,166,314,233,020.30$69,753$14,065.80+$1401535.22MAIFER
10$8,448,980,385,486$6,949,337,622,226.25$102,337$24,771.77+$8448980.28MAIFER

AIFER vs ABBV: Complete Analysis 2026

AIFERStock

Aifeex Nexus Acquisition Corporation operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Full AIFER Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AIFER vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIFER vs SCHDAIFER vs JEPIAIFER vs OAIFER vs KOAIFER vs MAINAIFER vs JNJAIFER vs MRKAIFER vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.